206 related articles for article (PubMed ID: 2788981)
41. [In vitro immunization for the production of antibodies to tetanus toxin and toxoid. 2. Antibody production in lymphocyte cultures].
Jahn S; Kiessig ST; Grunow R; von Baehr R
Allerg Immunol (Leipz); 1987; 33(2):89-94. PubMed ID: 2959130
[TBL] [Abstract][Full Text] [Related]
42. Human monoclonals against erythrocyte antigens.
Ernst M; Sonneborn HH
Hum Antibodies Hybridomas; 1990; 1(3):122-5. PubMed ID: 1966475
[TBL] [Abstract][Full Text] [Related]
43. [Monoclonal antibodies from the hybridization of lymphocytes].
Ax W
Ric Clin Lab; 1983; 13 Suppl 2():1-9. PubMed ID: 6366991
[No Abstract] [Full Text] [Related]
44. Anti-bacterial specificities in the human fetal B cell repertoire.
Settmacher U; Delvig A; Jahn S
Hum Antibodies Hybridomas; 1994; 5(1-2):91-5. PubMed ID: 7858188
[TBL] [Abstract][Full Text] [Related]
45. Microscale production of hybridomas by hypo-osmolar electrofusion.
Zimmermann U; Klöck G; Gessner P; Sammons DW; Neil GA
Hum Antibodies Hybridomas; 1992 Jan; 3(1):14-8. PubMed ID: 1576318
[TBL] [Abstract][Full Text] [Related]
46. Novel approach to construction of human "myeloma analogues" for production of human monoclonal antibodies.
Posner MR; Schlossman SF; Lazarus H
Hybridoma; 1983; 2(4):369-81. PubMed ID: 6678803
[TBL] [Abstract][Full Text] [Related]
47. [A strategy for the production of human monoclonal antibodies].
Chiba J
Hum Cell; 1988 Mar; 1(1):31-6. PubMed ID: 2856441
[TBL] [Abstract][Full Text] [Related]
48. Human-human B cell hybridomas from in vitro stimulated lymphocytes of patients with common variable immunodeficiency.
Denis KA; Wall R; Saxon A
J Immunol; 1983 Nov; 131(5):2273-8. PubMed ID: 6313803
[TBL] [Abstract][Full Text] [Related]
49. The generation of Ig-secreting UC 729-6 derived human hybridomas by electrofusion.
Pratt M; Mikhalev A; Glassy MC
Hybridoma; 1987 Oct; 6(5):469-77. PubMed ID: 3500113
[TBL] [Abstract][Full Text] [Related]
50. Reproducible production of protective human monoclonal antibodies by fusion of peripheral blood lymphocytes with a mouse myeloma cell line.
Gigliotti F; Smith L; Insel RA
J Infect Dis; 1984 Jan; 149(1):43-7. PubMed ID: 6607295
[TBL] [Abstract][Full Text] [Related]
51. Analysis of factors affecting human hybridoma production.
Watts RA; Winska-Wiloch H; Muller S; Isenberg DA
Hum Antibodies Hybridomas; 1990; 1(3):160-5. PubMed ID: 2103360
[TBL] [Abstract][Full Text] [Related]
52. [A new approach to the design of hybrid hybridomas based on the use of an actinomycin D-resistant line of murine myeloma].
Massino IuS; Kizim EA; Dmitriev AD
Biull Eksp Biol Med; 1991 Nov; 112(11):511-4. PubMed ID: 1687361
[TBL] [Abstract][Full Text] [Related]
53. Development of mouse hybridomas by fusion of myeloma cells with lymphocytes derived from spleen, lymph node, and bone marrow.
Başalp A; Yücel F
Hybrid Hybridomics; 2003 Oct; 22(5):329-31. PubMed ID: 14678651
[TBL] [Abstract][Full Text] [Related]
54. Parameters to enhance human hybridoma formation with hypoosmolar electrofusion.
Perkins S; Zimmermann U; Foung SK
Hum Antibodies Hybridomas; 1991 Jul; 2(3):155-9. PubMed ID: 1651789
[TBL] [Abstract][Full Text] [Related]
55. Preparation of human-mouse heterohybridomas against an immunising antigen.
Jessup CF; Baxendale H; Goldblatt D; Zola H
J Immunol Methods; 2000 Dec; 246(1-2):187-202. PubMed ID: 11121559
[TBL] [Abstract][Full Text] [Related]
56. Hybridoma Technology.
Hnasko RM; Stanker LH
Methods Mol Biol; 2015; 1318():15-28. PubMed ID: 26160560
[TBL] [Abstract][Full Text] [Related]
57. Preferential generation of monoclonal IgG-producing hybridomas by use of vesicular stomatitis virus-mediated cell fusion.
Nagata S; Yamamoto K; Ueno Y; Kurata T; Chiba J
Hybridoma; 1991 Jun; 10(3):369-78. PubMed ID: 1655635
[TBL] [Abstract][Full Text] [Related]
58. An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies.
Yu X; McGraw PA; House FS; Crowe JE
J Immunol Methods; 2008 Jul; 336(2):142-51. PubMed ID: 18514220
[TBL] [Abstract][Full Text] [Related]
59. Characterization of mouse-human hybridoma as a useful fusion partner for the establishment of mouse-human-human hybridoma secreting anti-tetanus toxoid human monoclonal antibody of IgM or IgG class.
Hirata Y; Sugawara I
Microbiol Immunol; 1987; 31(3):231-45. PubMed ID: 3613992
[TBL] [Abstract][Full Text] [Related]
60. Human hybridomas derived from CD5+ B lymphocytes of patients with chronic lymphocytic leukemia (B-CLL) produce multi-specific natural IgM (kappa) antibodies.
Jahn S; Schwab J; Hansen A; Heider H; Schroeder C; Lukowsky A; Achtman M; Matthes H; Kiessig ST; Volk HD
Clin Exp Immunol; 1991 Mar; 83(3):413-7. PubMed ID: 1706236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
